Nutriband Inc. announces exercise of warrants at $6.43 for Gross Proceeds of $5,306,000
Nutriband (NASDAQ:NTRB) has announced the exercise of warrants at a strike price of $6.43, generating gross proceeds of $5,306,000. The company will utilize these funds primarily for completing the clinical development of AVERSA Fentanyl and submitting its New Drug Application (NDA) to the FDA for marketing approval.
AVERSA Fentanyl is positioned to potentially become the first opioid patch with abuse deterrent properties. According to the Health Advances Aversa Fentanyl market analysis report 2022, the product could achieve peak annual US sales between $80 million to $200 million.
Nutriband (NASDAQ:NTRB) ha comunicato l'esercizio di warrant con un prezzo di esercizio di $6.43, raccogliendo proventi lordi pari a $5.306.000. L'azienda utilizzerà principalmente questi fondi per completare lo sviluppo clinico di AVERSA Fentanyl e per presentare la New Drug Application (NDA) alla FDA per l'autorizzazione alla commercializzazione.
AVERSA Fentanyl punta a diventare, potenzialmente, la prima cerotto eufentanyl con caratteristiche di deterrenza all'abuso. Secondo il rapporto di analisi di mercato Health Advances Aversa Fentanyl 2022, il prodotto potrebbe raggiungere un picco di vendite annue negli USA compreso tra $80 milioni e $200 milioni.
Nutriband (NASDAQ:NTRB) ha anunciado el ejercicio de warrants a un precio de ejercicio de $6.43, generando ingresos brutos por $5.306.000. La compañía empleará estos fondos principalmente para completar el desarrollo clínico de AVERSA Fentanyl y presentar la New Drug Application (NDA) ante la FDA para la aprobación de comercialización.
AVERSA Fentanyl aspira a convertirse, potencialmente, en el primer parche de opioide con propiedades que disuaden el abuso. Según el informe de análisis de mercado Health Advances Aversa Fentanyl 2022, el producto podría alcanzar ventas anuales máximas en EE. UU. de entre $80 millones y $200 millones.
Nutriband (NASDAQ:NTRB)는 행사가 $6.43인 워런트를 행사해 총 $5,306,000의 총수익을 확보했다고 발표했습니다. 회사는 이 자금을 주로 AVERSA Fentanyl의 임상 개발 완료와 FDA에 시판 승인 신청인 신약 허가서(NDA)를 제출하는 데 사용할 예정입니다.
AVERSA Fentanyl은 남용 방지 특성을 갖춘 최초의 오피오이드 패치가 될 가능성을 목표로 하고 있습니다. Health Advances의 Aversa Fentanyl 시장 분석 보고서(2022)에 따르면 이 제품은 미국에서 연간 최대 매출이 $8,000만에서 $2억 사이에 이를 수 있습니다.
Nutriband (NASDAQ:NTRB) a annoncé l'exercice de bons de souscription (warrants) à un prix d'exercice de $6.43, générant des recettes brutes de $5 306 000. La société utilisera principalement ces fonds pour achever le développement clinique de AVERSA Fentanyl et déposer sa New Drug Application (NDA) auprès de la FDA en vue de l'autorisation de mise sur le marché.
AVERSA Fentanyl pourrait devenir, potentiellement, le premier patch d'opioïde doté de propriétés dissuasives contre l'abus. Selon le rapport d'analyse de marché Health Advances Aversa Fentanyl 2022, le produit pourrait atteindre des ventes annuelles maximales aux États-Unis comprises entre 80 et 200 millions de dollars.
Nutriband (NASDAQ:NTRB) hat die Ausübung von Warrants zu einem Ausübungspreis von $6.43 angekündigt und damit Bruttoerlöse in Höhe von $5.306.000 erzielt. Das Unternehmen wird diese Mittel vorwiegend dafür verwenden, die klinische Entwicklung von AVERSA Fentanyl abzuschließen und seine New Drug Application (NDA) zur Zulassung bei der FDA einzureichen.
AVERSA Fentanyl zielt darauf ab, möglicherweise das erste Opioid-Pflaster mit missbrauchsverhindernden Eigenschaften zu werden. Laut dem Marktanalysebericht Health Advances Aversa Fentanyl 2022 könnte das Produkt in den USA Spitzenjahresumsätze von $80 Millionen bis $200 Millionen erreichen.
- Successful warrant exercise generating $5.3M in proceeds
- AVERSA Fentanyl potential peak sales of $80M-$200M annually
- Development of first-in-class abuse deterrent opioid patch
- Additional funding may be needed to complete clinical development and FDA submission
- FDA approval not guaranteed despite development progress
ORLANDO, Fla., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of abuse deterrent pharmaceutical products announced today that it has seen warrants exercised at a strike price of
The primary use of proceeds will be used towards the remaining clinical development of AVERSA Fentanyl and submission of its NDA with the FDA for marketing approval. AVERSA Fentanyl has the potential to become the world's first opioid patch with abuse deterrent properties and is estimated it could reach peak annual US sales of
1 Health Advances Aversa Fentanyl market analysis report 2022
About Nutriband Inc.
We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse-deterrent fentanyl patch incorporating our AVERSA™ abuse-deterrent technology. AVERSA™ technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
The Company’s website is www.nutriband.com. Any material contained in or derived from the Company’s websites or any other website is not part of this press release.
Forward-Looking Statements
Certain statements contained in this press release, including, without limitation, statements containing the words “believes,” “anticipates,” “expects” and words of similar import, constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks and uncertainties. The Company’s actual results may differ materially from those anticipated in its forward-looking statements as a result of a number of factors, including the Company’s ability to develop its proposed abuse-deterrent fentanyl transdermal system and other proposed products, its ability to obtain patent protection for its abuse technology, its ability to obtain the necessary financing to develop products and conduct the necessary clinical testing, its ability to obtain Federal Food and Drug Administration approval to market any product it may develop in the United States and to obtain any other regulatory approval necessary to market any product in other countries, including countries in Europe, its ability to market any product it may develop, its ability to create, sustain, manage or forecast its growth; its ability to attract and retain key personnel; changes in the Company’s business strategy or development plans; competition; business disruptions; adverse publicity and international, national and local general economic and market conditions and risks generally associated with an undercapitalized developing company, as well as the risks contained under “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the Company’s Form S-1, Forms 10-K’s and Forms 10-Q’s, and the Company’s other filings with the Securities and Exchange Commission. Except as required by applicable law, we undertake no obligation to revise or update any forward-looking statements to reflect any event or circumstance that may arise after the date hereof.
Contact Information:
Nutriband Inc.
Phone: 407-377-6695
Email: info@nutriband.com
SOURCE: Nutriband Inc.
FAQ
How much did Nutriband (NTRB) raise through warrant exercise in September 2025?
What is the projected market potential for AVERSA Fentanyl?
What will Nutriband use the warrant exercise proceeds for?
What makes AVERSA Fentanyl unique in the market?
What is the current development stage of Nutriband's AVERSA Fentanyl?
